Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olmesartan medoxomil/hydrochlorothiazide - Daiichi Sankyo

Next Previous
X
Search
Drug Profile

Olmesartan medoxomil/hydrochlorothiazide - Daiichi Sankyo

Alternative Names: Benicar HCT; CS-866CMB; Olmetec Plus; Openvas Co; Votum Plus

Latest Information Update: 21 Jan 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer AbbVie; Daiichi Sankyo Company; Menarini
  • Class Antihypertensives; Benzothiadiazines; Imidazoles; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 18 Jan 2022 Olmesartan medoxomil/hydrochlorothiazide licensed to Cosette Pharmaceuticals in USA
  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 26 Oct 2016 First generic equivalent launched in USA for Hypertension (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top